Craft

Mainz BioMed

Stock Price

$1

2024-03-25

Market Capitalization

$21 M

2024-03-25

Revenue

$529 K

FY, 2022

Mainz BioMed Summary

Company Summary

Overview
Mainz BioMed is a molecular genetics cancer diagnostic company that manufactures in-vitro diagnostic (IVD) tests. It offers ColoAlert, a colorectal cancer screening stool-based DNA (deoxyribonucleic acid) test, PancAlert, a product candidate for a pancreatic cancer screening test, GenoStrip, a proposed platform technology to detect pathogens or genetic aberrations, and the GenoChips and the HumaSense product line. The company caters to the cancer industry.
Type
Public
Status
Active
Founded
2021
HQ
Mainz, DE | view all locations
Website
https://mainzbiomed.com/
Cybersecurity rating
Sectors

Key People

  • Guido Baechler

    Guido Baechler, Chief Executive Officer, Director

  • William Caragol

    William Caragol, Chief Financial Officer

  • Moritz Eidens
  • Philipp Freese

LocationsView all

1 location detected

  • Mainz, RP HQ

    Germany

    Robert-Koch-Straße 50

Mainz BioMed Financials

Summary Financials

Revenue (Q3, 2023)
$181.0K
Gross profit (Q3, 2023)
$87.0K
Net income (Q3, 2023)
($6.3M)
Cash (Q2, 2023)
$10.9M
EBIT (Q3, 2023)
($6.3M)
Enterprise value
$21.9M

Footer menu